SYNTHESIS AND ANTIBACTERIAL EVALUATION OF NOVEL 3,6-DISUBSTITUTED COUMARIN DERIVATIVES

Ravibabu Velpula, Ramesh Gondru, Yashodhara Velivela, and Rajitha Bavantula

1Department of Chemistry, National Institute of Technology, Warangal, India
2Department of Biotechnology, Kakatiya University, Warangal, India

Abstract A novel series of 3,6-disubstituted coumarin derivatives were synthesized by the reaction of ethyl-2-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-methylthiazole-5-carboxylate with thiosemicarbazide and various phenacyl bromides / 3-(2-bromoacetyl)-2H-chromen-2-ones / 2-(2-bromoacetyl)-3H-benzo[f]chromen-3-one in ethanol having catalytic amount of acetic acid under reflux conditions with good yields. All the synthesized compounds were fully characterized by spectral studies and evaluated for their in vitro antibacterial activity against Pseudomonas aeruginosa, Bacillus subtilis (Gram positive), Escherichia coli, and Azatobacter (Gram negative) bacterial strains. Activity results revealed that the compound 6h against Escherichia coli and compound 6i against Pseudomonas aeruginosa and Escherichia coli have shown maximum zones of inhibition. Remaining compounds showed moderate to good activity against all the tested bacterial strains compared with the standard drug cefotaxime.

Keywords Antibacterial activity; 3,6-disubstituted coumarins; thiazole

INTRODUCTION

The natural and synthetic coumarin derivatives played an important role in medicinal chemistry because of their biological and pharmacological properties. Hence the synthesis of various coumarin derivatives occupied an important place

Received July 28, 2014.
Address correspondence to Rajitha Bavantula, Department of Chemistry, National Institute of Technology, Warangal 506004, A.P., India. E-mail: rajitabhargavi@yahoo.com
Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/lsyc.
in organic synthesis. Coumarins and their derivatives displayed antimicrobial,\textsuperscript{[1,2]} antiviral,\textsuperscript{[3]} anticancer,\textsuperscript{[4]} anti-inflammatory,\textsuperscript{[5]} antioxidant,\textsuperscript{[6]} anti-HIV,\textsuperscript{[7]} and antiasthmatic\textsuperscript{[8]} activities. These also act as acetylcholinesterase\textsuperscript{[9]} and monoamine oxidase\textsuperscript{[10]} inhibitors for depression and Alzheimer’s disease. In particular, 3,6-disubstituted comarins act as mechanism-based inhibitors of thrombin and factor Xa.\textsuperscript{[11]} Similarly, numerous biologically active molecules have thiazole rings as an integral part of their structure. This nucleus constitutes an integral part of all the available penicillins\textsuperscript{[12]} for controlling bacterial diseases. The literature survey revealed that thiazoles act as antimicrobial,\textsuperscript{[13,14]} antitumor,\textsuperscript{[15]} anti-inflammatory,\textsuperscript{[16]} anticonvulsant,\textsuperscript{[17]} and anticoagulant\textsuperscript{[18]} agents. In view of the therapeutic properties of these moieties (coumarins and thiazoles), as well as in continuation of our earlier studies on coumarin derivatives,\textsuperscript{[19–21]} we report the design and synthesis of a novel series of 3,6-disubstituted coumarin derivatives under conventional method.\textsuperscript{[22,23]}

RESULTS AND DISCUSSION

Ethyl-2-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-methylthiazole-5-carboxylate (3) was prepared from ethyl-2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate (1) and ethylacetooacetate (2) in the presence of a base by Knoevenagel reaction. The title compounds, 3,6-disubstituted coumarin derivatives (6a–l) that incorporated two important pharmacophores (coumarin, thiazole heterocycle), were synthesized by one-pot multicomponent condensation of ethyl-2-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-methylthiazole-5-carboxylate (3), thiosemicarbazide (4), and various phenacyl bromides (5a–g) / 3-(2-bromoacetyl)-2H-chromen-2-one derivatives (5h–k) / 2-(2-bromoacetyl)-3H-benzo[f]chromen-3-one (5l) in ethanol with a catalytic amount of acetic acid under reflux conditions (Scheme 1) with good yields (Table 1). All the synthesized compounds were confirmed by spectroscopic (IR, \textsuperscript{1}H NMR, \textsuperscript{13}C NMR,
| Entry | Compound | Time (h) | Yield (%) |
|-------|----------|----------|-----------|
| 1     | ![6a](image) | 2        | 88        |
| 2     | ![6b](image) | 3        | 90        |
| 3     | ![6c](image) | 3        | 89        |
| 4     | ![6d](image) | 3        | 82        |
| 5     | ![6e](image) | 2        | 86        |
| 6     | ![6f](image) | 2        | 92        |
| Entry<sup>a</sup> | Compound | Time (h) | Yield (%)<sup>b</sup> |
|------------------|-----------|----------|-----------------------|
| 7                | ![6g](image) | 3        | 84                    |
| 8                | ![6h](image) | 4        | 87                    |
| 9                | ![6i](image) | 4        | 78                    |
| 10               | ![6j](image) | 3        | 80                    |
| 11               | ![6k](image) | 2        | 76                    |
| 12               | ![6l](image) | 3        | 84                    |

<sup>a</sup> Reaction conditions: 4-substituted phenacyl bromide (5a–g) / 3-(2-bromoacetyl)-2H-chromen-2-ones (5h–k) / 2-(2-bromoacetyl)-3H-benzo[f]chromen-3-one (5l) (1 mmol), thiosemicarbazide (4.1 mmol), and ethyl-2-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-methylthiazole-5-carboxylate (3.1 mmol), ethanol + cat. acetic acid, reflux.

<sup>b</sup> Yields refers to isolated products.
and mass) and elemental analysis. In IR spectra, the presence of lactone and imine functional groups was confirmed by absorption at ν 1717–1742 and 1598–1631 cm⁻¹ respectively, as well as other characteristic absorption bands. ¹H NMR spectroscopic analysis revealed the diagnostic resonances for the coumarin (4-H) protons at δ 8.54–8.76 ppm as singlets. In addition, the molecular ion peak from the mass spectra and elemental analyses data further support the formation of products.

**Antibacterial Activity**

All the newly synthesized compounds (6a–l) were assessed for their *in vitro* antibacterial activity against *Pseudomonas aeruginosa*, *Bacillus subtilis* (Gram positive), *Escherichia coli*, and *Azatobacter* (Gram negative) bacterial strains compared to standard antibiotic drug cefotaxime. Zone of inhibition (mm) values for analogues and positive control drug cefotaxime were determined by agar disc diffusion method.[24] The bacterial strains were grown and maintained on nutrient agar plates. All the compounds and standard were dissolved in dimethylsulfoxide (DMSO; 100µg/mL and 30µg/mL respectively) and transferred to each disc with the help of micropipette. After 24 h incubation at 37°C, the resulting zone of inhibition was measured.

The antibacterial data revealed that almost all the compounds 6a–l have shown moderate to good antibacterial activity (Table 2). Compounds 6f, 6h–k, and 6l have shown good activity whereas compounds 6a, 6b, 6d, 6g have shown moderate activity against both Gram-positive and Gram-negative strains. Compound 6c is inactive towards *Bacillus subtilis* and *Escherichia coli*, whereas compound 6e is inactive only on *Bacillus subtilis*. In the overview of antibacterial data, compound 6h against *Escherichia coli* and compound 6i against *Pseudomonas aeruginosa* and *Escherichia coli* have shown maximum zones of inhibition (11 mm) when compared with the

| Analogue | Zone of inhibition (mm) | Gram positive | Gram negative |
|----------|-------------------------|---------------|---------------|
|          |                         | *Pseudomonas aeruginosa* | *Bacillus subtilis* | *Escherichia coli* | *Azatobacter* |
| 6a       | 5                       | 4              | 7              | 6              |
| 6b       | 8                       | 8              | 9              | 5              |
| 6c       | 4                       | —              | —              | 8              |
| 6d       | 5                       | 4              | 4              | 7              |
| 6e       | 6                       | —              | 7              | 5              |
| 6f       | 9                       | 8              | 9              | 9              |
| 6g       | 6                       | 7              | 7              | 5              |
| 6h       | 10                      | 10             | 11             | 9              |
| 6i       | 11                      | 9              | 11             | 9              |
| 6j       | 9                       | 5              | 9              | 11             |
| 6k       | 8                       | 10             | 8              | 9              |
| 6l       | 9                       | 8              | 8              | 10             |
| Cefotaxime | 14                     | 14             | 13             | 13             |

*Note.* — indicates not active.
standard drug cefotaxime. The graphical representation of antibacterial activity of the compounds as well as standard drug cefotaxime are shown in Fig. 1.

EXPERIMENTAL

All the reagents and solvents were purchased from Aldrich/Merck and used without further purifications. Melting points were determined in open capillaries using Stuart SMP30 apparatus and are uncorrected. The progress of the reactions as well as purity of compounds were monitored by thin-layer chromatography (TLC) with F254 silica-gel precoated sheets using hexane/ethyl acetate 8/2 as eluent; ultraviolet light and iodine vapors were used for detection. IR spectra were recorded on a Perkin-Elmer 100S spectrometer utilizing KBr pellets. 1H NMR and 13C NMR spectra were obtained at 400 MHz and 100 MHz respectively on Bruker using dimethylsulfoxide (DMSO-d6) as solvent and tetramethylsilane (TMS) as internal standard. Elemental analyses were performed on a Carlo-Erba model EA1108 analytical unit and the values are ±0.4% of theoretical values. Mass spectra were recorded on a Jeol JMSD-300 spectrometer.

**General Procedure for the Synthesis of Ethyl-2-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-methylthiazole-5-carboxylate (3)**

A mixture of ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate (1, 0.1 mol) and ethylacetocetate (2, 0.12 mol) were dissolved in ethanol and cooled at 0–5 °C. Piperidine (1 mL) was added dropwise to this mixture while stirring. The reaction mixture was left overnight, resulting in the formation of a yellow-colored solid. Purification by recrystallization from ethanol afforded the analytically pure product.

**General Procedure for the Synthesis of 3,6-Disubstituted Coumarin Derivatives (6a–l)**

A mixture of ethyl-2-(3-acetyl-2-oxo-2H-chromen-6-yl)-4-methylthiazole-5-carboxylate (3, 1 mmol), thiosemicarbazide (4, 1 mmol), and various phenacyl bromides
(5a–g) / 3-(2-bromoacetyl)-2H-chromen-2-ones (5h–k) / 2-(2-bromoacetyl)-3H-benzo [f]chromen-3-one (5l) (1 mmol) were dissolved in 10 mL of absolute ethanol in the presence of a catalytic amount of acetic acid and heated at refluxing temperature for 2–4 h. The reaction was monitored by TLC. Contents were poured into ice-cold water, and the solid obtained was filtered, dried, and recrystallized in ethanol.

**Ethyl-4-methyl-2-(2-oxo-3-(1-(2-(4-phenylthiazol-2-yl)hydrazono)ethyl)-2H-chromen-6-yl)thiazole-5-carboxylate (6a)**

Pale yellow solid; mp 224–226°C; IR (KBr, cm⁻¹) νmax: 3404 (NH), 1741 (C=O), 1718 (C=O), 1611, (C=N) 1565 (C=C); ¹H NMR (400 MHz, DMSO-d₆): δ 1.31 (t, 3H, J = 7.2 Hz), 2.29 (s, 3H), 2.71 (s, 3H), 4.28–4.33 (m, 2H), 7.29–7.44 (m, 2H), 7.55 (d, 1H, J = 8.8 Hz), 7.89 (d, 2H, J = 7.2 Hz), 8.19–8.22 (m, 1H), 8.30 (s, 1H), 8.56–8.62 (m, 2H), 8.74 (s, 1H), 11.45 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ 14.0, 16.0, 17.1, 61.2, 104.4, 116.9, 119.5, 121.5, 125.5, 127.2, 127.4, 128.5, 129.7, 134.5, 139.9, 144.4, 154.7, 158.5, 160.2, 161.2, 167.3, 169.2; MS (ESI) m/z: 531 [M + 1]⁺. Anal. calcd. for C₂₇H₂₂N₄O₄S₂: C, 61.12; H, 4.18; N, 10.56. Found: C, 61.24; H, 4.06; N, 10.61.

**CONCLUSION**

In conclusion, we have synthesized a novel series of 3,6-disubstituted coumarin derivatives by using conventional methods. All synthesized compounds were determined from their spectral (IR, ¹H NMR, ¹³C NMR) and mass data and assessed for their in vitro antibacterial activity.

**ACKNOWLEDGMENT**

We thank the director of the National Institute of Technology, Warangal, for providing facilities.

**FUNDING**

R. V. thanks the University Grants Commission for providing a research fellowship.

**SUPPORTING INFORMATION**

Supplemental data for this article can be accessed on the publisher’s website.

**REFERENCES**

1. Arshad, A.; Osman, H.; Bagley, M. C.; Lam, C. K.; Mohamad, S.; Zahariluddin, A. S. M. Eur. J. Med. Chem. 2011, 46, 3788–3794.
2. Curir, P.; Galeotti, F.; Dolci, M.; Barile, E.; Lanzotti, V. J. Nat. Prod. 2007, 70, 1668--1671.
3. Mazzei, M.; Nieddu, E.; Miele, M.; Balbi, A.; Ferrone, M.; Fermeglia, M.; Mazzei, M. T.; Pricl, S.; Colla, P. L.; Marongiu, F.; Ibbac, C.; Loddo, R. Bioorg. Med. Chem. 2008, 16, 2591–2605.
4. Nasr, T.; Bondock, S.; Youns, M. Eur. J. Med. Chem. 2014, 76, 539–548.
5. Stefani, H. A.; Gueogjan, K.; Manarin, F.; Farsky, S. H. P.; Zukerman-Schpector, J.; Caracelli, I.; Rodrigues, S. R. P.; Muscará, M. N.; Teixeira, S. A.; Santin, J. R.; Machado, I. D.; Bolonheis, S. M.; Curi, R.; Vinolo, M. A. Eur. J. Med. Chem. 2012, 58, 117–127.
6. Roussaki, M.; Kontogiorgis, C. A.; Hadjipavlou-Litina, D.; Hamilakis, S.; Detsi, A. Bioorg. Med. Chem. Lett. 2010, 20, 3889–3892.
7. Kirkiacharian, S.; Thuy, D.; Sicisic, S.; Bakhchinian, R.; Kurkjian, R.; Tonnaire, T. Farmaco. 2002, 57, 703–708.
8. Sanchez-Recillas, A.; Navarrete-Vázquez, G.; Hidalgo-Figueroa, S.; Rios, M. Y.; Ibarra-Barajas, M.; Estrada-Sotoa, S. Eur. J. Med. Chem. 2014, 77, 400–408.
9. Nama, S. O.; Parka, D. H.; Leea, Y. H.; Ryua, J. H.; Leea, Y. S. Bioorg. Med. Chem. 2014, 77, 400–408.
10. Pravin, O. P.; Sanjay, B. B.; Sandip, D. F.; Prashant, K. D.; Shailesh, T. D.; Dilip, A. P. Bioorg. Med. Chem. 2013, 21, 2434–2450.
11. Frederick, R.; Robert, S.; Charlfer, C.; de Ruyck, J.; Wouters, J.; Pirotte, B.; Masereel, B.; Pochet, L. J. Med. Chem. 2005, 48, 7592–7603.
12. Oncu, M.; Panar, M.; Erakosy, H. Chemotherapy 2004, 50, 98–100.
13. Omar, K.; Geronikoki, A.; Zoumpoulakis, P.; Camoutsis, C.; Sokovic, M.; Ciric, A. Glamoclija, J. Bioorg. Med. Chem. 2010, 18, 426–432.
14. Liaras, K.; Geronikoki, A.; Glamoclija, J.; Ciric, A.; Sokovic, M. Bioorg. Med. Chem. 2011, 19, 3135–3140.
15. Hassana, G. S.; El-Messeryc, S. M.; Al-Omarya, F. A. M.; El-Subbaghd, H. I. Bioorg. Med. Chem. Lett. 2012, 22, 6318–6323.
16. Sharma, R. N.; Xavier, F. P.; Vasu, K. K.; Chaturvedi, S. C.; Pancholi, S. S. J. Enzym. Inhib. Med. Chem. 2009, 24, 890–897.
17. Chakole, R. D.; Amnerkar, N. D.; Khedekar, P. B.; Bhusari, K. P. Indian. J. Heterocycl. Chem. 2005, 15, 27–30.
18. Amr, A. E. E.; Sabry, N. M.; Abdalla, M. M.; Abdel-Wahab, B. F. Eur. J. Med. Chem. 2009, 44, 725–735.
19. Kuarm, B. S.; Reddy, Y. T.; Madhav, J. V.; Crooks, P. A.; Rajitha, B. Bioorg. Med. Chem. Lett. 2011, 21, 524–527.
20. Laxmi, S. V.; Reddy, Y. T.; Kuarm, B. S.; Reddy, P. N.; Crooks, P. A.; Rajitha, B. Bioorg. Med. Chem. Lett. 2011, 21, 4329–4331.
21. Janardhan, B.; Rajitha, B. Chin. Chem. Lett. 2012, 23, 1015–1018.
22. Secci, D.; Bizzarri, B.; Bolasco, A.; Carradori, S.; D’Ascenzo, M.; Rivanera, D.; Mari, E.; Polletta, L.; Zicari, A. Eur. J. Med. Chem. 2012, 53, 246–253.
23. Chimenti, F.; Bizzarri, B.; Bolasco, A.; Secci, D.; Chimenti, P.; Granese, A.; Carradori, S.; D’Ascenzo, M.; Lilli, D.; Rivanera, D. Eur. J. Med. Chem. 2011, 46, 378–382.
24. Reddy, P. M.; Ho, Y. P.; Shanker, K.; Rohini, R.; Ravinder, V. Eur. J. Med. Chem. 2009, 44, 2621–2625.